Provention Bio

company

About

Provention Bio is a clinical stage biopharmaceutical dedicated to sourcing, developing and commercializing novel therapeutics.

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$125M
Industries
Biotechnology,Health Care,Medical,Pharmaceutical
Founded date
Oct 4, 2016
Number Of Employee
51 - 100
Operating Status
Active
Stock Symbol
nasdaq:PRVB
Legal Name
Provention Bio, Inc.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease.

Their “predict and prevent” model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears or progresses. As such, we believe Provention is well-positioned to become a leader in a new biopharmaceutical category centered on the interception of disease, offering the potential to reduce the high-morbidity, mortality, patient suffering and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections.
Provention has been carefully conceived, founded and positioned to be at the forefront of this pioneering new paradigm in medicine. They believe Provention’s business model, coupled with our expertise in translational medicine, immunology and the design and execution of rapid go/no-go clinical trials, will enable us to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$487.40M
Provention Bio has raised a total of $487.40M in funding over 2 rounds. Their latest funding was raised on Aug 31, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 31, 2022 Post-IPO Debt $125M 1 Hercules Capital Detail
Jul 7, 2022 Post-IPO Equity $60M 2 Armistice Capital
Sessa Capital
Detail
Jan 13, 2021 Post-IPO Equity $100M Detail
Jun 22, 2020 Post-IPO Equity $110.10M Detail
Jul 19, 2018 IPO $63.90M Detail

Investors

Number of Lead Investors
Number of Investors
4
6
Provention Bio is funded by 6 investors. Hercules Capital and Armistice Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Post-IPO Debt
Armistice Capital Yes Post-IPO Equity
Sessa Capital Yes Post-IPO Equity
Johnson & Johnson Innovation Yes Series A
JDRF T1D Fund Series A
MDB Capital Group Series A

Employee Profiles

Number of Employee Profiles
14
Provention Bio has 14 current employee profiles, including Employee Rob Adamoski
Employee
Executive
Employee
Executive
Board member